FIELD: medicine.
SUBSTANCE: invention is an ophthalmic composition for administration to a silicone hydrogel contact lens for treatment, prevention or alleviation of dry eye syndrome, wherein the composition comprises an anti-inflammatory lipoid mediator ester in an amount of about 0.01% to 5.0% by weight, calculated for the total weight of the composition, wherein the anti-inflammatory lipid mediator is ethyl alpha-linoleic acid ether and propylene glycol, wherein the anti-inflammatory lipoid mediator is present in the form of an ester.
EFFECT: Improved absorption of an ester of an anti-inflammatory lipoid mediator in a silicone hydrogel contact lens.
12 cl, 13 ex, 12 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| ESTERS FOR TREATING OPHTHALMIC INFLAMMATORY DISEASES | 2012 |
|
RU2707961C2 |
| ESTERS FOR OPHTHALMOLOGICAL INFLAMMATORY DISEASES TREATMENT | 2012 |
|
RU2627438C2 |
| ESTERS FOR TREATMENT OF OPHTHALMIC INFLAMMATORY DISEASES | 2012 |
|
RU2747953C2 |
| COMPOUND ETHERS FOR TREATMENT OF OPHTHALMOLOGICAL INFLAMMATORY DISEASES | 2012 |
|
RU2673230C1 |
| COMPOSITIONS BASED ON PARTIALLY FLUORINATED ALKANES, CONTAINING ETHYL ESTERS OF OMEGA-3 FATTY ACIDS | 2019 |
|
RU2808451C2 |
| PHARMACEUTICAL FORMULATIONS OF NON-POLAR AND POLAR LIPIDS FOR OPHTHALMOLOGICAL APPLICATION | 2007 |
|
RU2495661C2 |
| OPHTHALMOLOGICAL COMPOSITION, BASED ON POLYUNSATURATED FATTY ACIDS OMEGA-3 AND OMEGA-6 | 2010 |
|
RU2545675C2 |
| COMPOSITIONS AND METHODS FOR EYE TREATMENT | 2019 |
|
RU2793736C2 |
| COMPOSITIONS AND METHODS OF TREATING EYE DISORDERS | 2019 |
|
RU2802365C2 |
| STABILIZED OPHTHALMIC COMPOSITIONS CONTAINING OMEGA-3-ACIDS | 2015 |
|
RU2697844C2 |
